Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 30.16
+1.40 (4.87%)
At close: Mar 6, 2026
Kexing Biopharm Revenue
In the year 2025, Kexing Biopharm had annual revenue of 1.54B CNY with 9.54% growth. Kexing Biopharm had revenue of 393.52M in the quarter ending December 31, 2025, with 6.74% growth.
Revenue
1.54B
Revenue Growth
+9.54%
P/S Ratio
3.88
Revenue / Employee
1.63M
Employees
971
Market Cap
5.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.54B | 134.23M | 9.54% |
| Dec 31, 2024 | 1.41B | 147.89M | 11.75% |
| Dec 31, 2023 | 1.26B | -56.84M | -4.32% |
| Dec 31, 2022 | 1.32B | 30.70M | 2.39% |
| Dec 31, 2021 | 1.29B | 64.88M | 5.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Xiangxue Pharmaceutical | 1.47B |
| Beijing Konruns Pharmaceutical | 871.31M |
| GemPharmatech | 793.25M |
| R&G PharmaStudies | 789.45M |
| PharmaResources (Shanghai) | 667.47M |
| Lifecome Biochemistry | 587.04M |